Co-Diagnostics (CODX) $5 Million Registered Direct Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Co-Diagnostics Announces $5.0 Million Registered Direct Offering Priced At-the-Market
January 24, 2020 8:00 AM ESTSALT LAKE CITY--(BUSINESS WIRE)-- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has entered into definitive agreements with institutional investors for the purchase of 3,448,278 shares of its common stock, at a purchase price per share of $1.45, in a registered direct offering priced at-the-marked under the Nasdaq rules. The closing of the offering is expected to occur on or about January 28, 2020, subject to the satisfaction of customary closing conditions.
H.C. Wainwright & Co. is... More
Co-Diagnostics, Inc. Designs Test for New Coronavirus Using CoPrimer™ Platform
January 23, 2020 6:30 AM ESTProprietary Company design process facilitates rapid response to health emergencies
SALT LAKE CITY--(BUSINESS WIRE)-- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that it has completed principle design work for a PCR screening test for new coronavirus, 2019-nCoV, intended to address potential need for detection of the virus.
An outbreak of respiratory illness caused by the pneumonia-like 2019-nCoV has spread rapidly over the past two weeks, after first being discovered in the... More
